RxDoctor Payments Data

Xiushi Liu, MD

Clinical Cardiac Electrophysiology · Arcadia, CANPI 1710925904

Payments from drug & device makers

$26,387in general payments, 2019–2025

Across 480 payments — averaging $54.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$9K
  • Boston Scientific$8K
  • Medtronic$3K
  • Biosense Webster, Inc.$2K
  • Edwards Lifesciences$523
  • Johnson & Johnson$384
  • plus $4K from 28 others

What the payments were for

  • Consulting fees$4,82225%
  • Travel & lodging$3,00116%
  • Food & beverage$11,39159%
  • Education$430%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,387 in reported general payments places this provider in the 35th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$969,012
Medicare patients
655
Services billed
4,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban507$475,781
VyndamaxTafamidis11$250,464
EntrestoSacubitril/Valsartan156$140,463
XareltoRivaroxaban100$110,146
FarxigaDapagliflozin Propanediol40$33,735
Repatha SureclickEvolocumab35$24,863
JardianceEmpagliflozin21$18,540
Flecainide Acetate269$9,749
VascepaIcosapent Ethyl18$7,872
Diltiazem 24hr Er (Cd)Diltiazem Hcl247$4,906
Metoprolol Succinate334$4,196
Disopyramide Phosphate14$2,681
Potassium Chloride102$2,042
Ranolazine ErRanolazine36$1,945
Propafenone Hcl52$1,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$274$726,244518 claims
NovartisEntresto$364$140,463156 claims
Johnson & JohnsonXarelto$384$110,146100 claims
AstraZenecaFarxiga$202$33,73540 claims
Boehringer IngelheimJardiance$294$18,54021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →